2024
MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model
Baassiri A, Maziarz J, Blackburn H, Maul-Newby H, VanOudenhove J, Zhang X, Matthews M, Paul S, Liu W, Sefik E, Salomonis N, Grimes H, Flavell R, Halene S. MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model. Blood 2024, 144: 1815-1815. DOI: 10.1182/blood-2024-211908.Peer-Reviewed Original ResearchPeripheral blood-mobilized stem cellsAcute myeloid leukemiaProgression to secondary acute myeloid leukemiaHematopoietic stem cellsWeeks post-engraftmentSecondary acute myeloid leukemiaStudies of myelodysplastic syndromesMyelodysplastic syndromeCD34+ cellsEngraftment levelsPeripheral bloodBone marrowK micePost-engraftmentMouse modelNSG miceMDS samplesEngraftment of human hematopoietic stem cellsEnhanced engraftmentProgression to acute myeloid leukemiaHealthy donor peripheral bloodHuman CD45+ cellsHuman hematopoietic stem cellsAnalysis of CD34+ cellsPercentage of lymphoid cells
2014
ΜΙSΤRG Mice Support Good-Risk AML Engraftment
Ellegast J, Saito Y, Flavell R, Manz M. ΜΙSΤRG Mice Support Good-Risk AML Engraftment. Blood 2014, 124: 3808. DOI: 10.1182/blood.v124.21.3808.3808.Peer-Reviewed Original ResearchGood-risk acute myeloid leukemiaRisk acute myeloid leukemiaAcute myeloid leukemiaAML engraftmentMISTRG miceEngraftment levelsNSG miceTherapeutic strategiesAML samplesGM-CSFAggressive acute myeloid leukemiaM-CSFHuman AML samplesBone marrow aspirationPeripheral blood analysisAggressiveness of diseaseBone marrow analysisGenetic alterationsExtent of engraftmentUnsatisfactory treatment optionsNovel therapeutic strategiesDirect therapeutic strategiesPreliminary data pointAML presentationCD19 depletion